CJC-1295 5mg/mL
CJC-1295 5mg/mL is used in prescriber-directed longevity, peptide, antioxidant, or skin-longevity protocols. Published evidence varies substantially by ingredient, so the page avoids unsupported disease-treatment claims.
CJC-1295 at 5 mg/mL is a lower-concentration sterile injectable formulation of the synthetic GHRH analog, providing the same pharmacological activity as the 10 mg/mL preparation but allowing prescribers to deliver the same milligram dose in a larger injection volume, or to administer smaller milligram doses with higher volumetric precision. CJC-1295 stimulates pituitary GHRH receptors to produce sustained, physiologically patterned growth hormone and IGF-1 elevation. Genesis Compounding prepares this as a prescription-only 503A compounded sterile injectable for patient-specific use; CJC-1295 is not FDA-approved for any indication.
| Active Ingredient | Pharmacologic Role |
|---|---|
| CJC-1295 5mg/mL | Synthetic GHRH analog at lower concentration for flexible dosing; same mechanism as 10 mg/mL—sustained pituitary GHRH receptor stimulation producing prolonged GH and IGF-1 secretion with ~6–8 day half-life via albumin-binding DAC modification. |
Route: Subcutaneous injection as prescribed.
- The lower concentration (5 mg/mL) allows the same milligram dose to be administered in a 2× larger volume compared to the 10 mg/mL formulation—useful for patients requiring very precise low-dose titration or those who find smaller injection volumes uncomfortable.
- Rotate injection sites (abdomen, thigh, upper arm) at each administration.
- Use aseptic technique with new sterile needle/syringe for each injection.
- Administer on an empty stomach when possible to minimize insulin-mediated somatostatin release.
Dosing is prescriber-determined. All dosing principles from the 10 mg/mL preparation apply:
- Due to the lower concentration, the same milligram dose requires 2× the injection volume; confirm prescribed volume carefully to avoid dosing errors.
- Human research doses of 30–90 mcg/kg (weekly) have been studied; prescriber calibrates dose to individual patient IGF-1 targets and clinical response.
- Weekly administration is feasible given the extended half-life; prescriber determines the schedule.
CJC-1295 (5 mg/mL): Mechanism of action is identical to the 10 mg/mL formulation. The DAC modification allows albumin binding and a biological half-life of ~6–8 days. Sustained GHRH receptor activation in pituitary somatotrophs drives GH synthesis, secretion, and subsequent hepatic IGF-1 production. Preserves physiologic pulsatile GH architecture compared to exogenous rhGH. The 5 mg/mL concentration reflects a compounding concentration choice only; pharmacodynamics are concentration-independent for a given milligram dose.
Clinical indications, monitoring parameters, and patient population considerations are identical to the CJC-1295 10 mg/mL preparation. The 5 mg/mL formulation is chosen by the prescriber for dosing convenience, patient preference for injection volume, or precise low-dose titration.
Prescriber monitoring:
- IGF-1 level monitoring to titrate to physiologic target range.
- Fasting glucose and insulin for assessment of insulin resistance.
- Clinical assessment for GH excess effects: fluid retention, arthralgias, carpal tunnel syndrome.
- Active malignancy is an absolute contraindication.
Contraindications:
- Active malignancy
- Hypersensitivity to CJC-1295 or formulation excipients
- Non-functional pituitary (no somatotroph reserve)
Warnings & Precautions:
- Not FDA-approved; investigational use in humans.
- At 5 mg/mL, dosing error risk: a given volume delivers half the dose compared to the 10 mg/mL formulation; verify prescribed volume carefully.
- Cardiovascular (flushing, transient hypotension) and endocrine (insulin resistance) effects as described for the 10 mg/mL preparation.
- Informed consent required.
Drug Interactions:
- Same as 10 mg/mL preparation: insulin/antidiabetics, glucocorticoids, thyroid hormones.
Common Side Effects: Injection site reactions; flushing, warmth, headache post-injection; water retention; arthralgias; possible insulin resistance.
Refrigerate at 2–8°C (36–46°F). Protect from light. Do not freeze. The 5 mg/mL preparation is more dilute and should be handled with the same care as 10 mg/mL—peptide stability depends on temperature control and light protection. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
Why is CJC-1295 available at two concentrations (5 mg/mL and 10 mg/mL)?
Different concentrations allow prescribers to individualize the injection volume for patient preference and dosing precision. The same milligram dose requires a 2× larger injection volume with the 5 mg/mL formulation compared to 10 mg/mL. Prescribers may prefer the lower concentration for fine dose titration or when very small milligram doses are required.
Is this a weaker version of CJC-1295?
No. The pharmacological activity of CJC-1295 depends on the milligram dose administered, not the concentration per mL. The 5 mg/mL formulation is not less effective than 10 mg/mL for the same prescribed milligram dose—the difference is only in the volume of solution required to deliver that dose.
Is this product FDA-approved?
No. CJC-1295 is not FDA-approved for any indication. This is a 503A compounded sterile preparation from Genesis Compounding for a specific patient based on a prescriber's order. Its use is investigational.
How do I avoid dosing errors with the lower concentration?
Always confirm with your prescriber whether the prescribed dose is in milligrams or milliliters. With a 5 mg/mL preparation, each 0.1 mL contains 0.5 mg—compared to 1 mg per 0.1 mL with the 10 mg/mL preparation. Use a precisely calibrated syringe and never estimate volume.
What monitoring is recommended during treatment?
Your prescriber will monitor serum IGF-1 levels to confirm adequate GH stimulation and avoid supraphysiologic elevation. Fasting glucose may be monitored for insulin resistance. Report fluid retention, joint pain, or unusual fatigue promptly.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.